Covid 19 Research Clinical Trials by Shray Alag

BI 764198

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (2)

	Name (Synonyms)	Correlation
drug94	ARALAST NP Wiki	0.71
drug1978	Matching placebo Wiki	0.41

Correlated MeSH Terms (7)

	Name (Synonyms)	Correlation
D004646	Emphysema NIH	0.50
D019896	Alpha 1-Antitrypsin Deficiency NIH	0.50
D051436	Renal Insufficiency, Chronic NIH	0.25

	Name (Synonyms)	Correlation
D007674	Kidney Diseases NIH	0.21
D029424	Pulmonary Disease, Chronic Obstructive NIH	0.20
D008173	Lung Diseases, Obstructive NIH	0.20
D008171	Lung Diseases, NIH	0.15

Correlated HPO Terms (5)

	Name (Synonyms)	Correlation
HP:0012622	Chronic kidney disease HPO	0.29
HP:0000077	Abnormality of the kidney HPO	0.24
HP:0006510	Chronic pulmonary obstruction HPO	0.24

	Name (Synonyms)	Correlation
HP:0006536	Pulmonary obstruction HPO	0.22
HP:0002088	Abnormal lung morphology HPO	0.16

Clinical Trials

Navigate: Correlations HPO

There are 2 clinical trials

1 Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 764198 in Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Evaluation of Midazolam Interaction (Open-label, 2-period Fixed Sequence Design, Intraindividual Comparison)

To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to explore the pharmacokinetics (PK) of BI 764198 after single and multiple oral dosing. In addition, the effect of BI 764198 on the pharmacokinetics of midazolam, given as an oral microdose, will be explored after multiple oral dosing.

NCT04102462

Conditions

Healthy

Interventions

Drug: BI 764198
Drug: Matching placebo

Primary Outcomes

Measure: Percentage of subjects with drug-related adverse events

Time: Up to Day 34

Secondary Outcomes

Measure: Multiple dose part - AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

Time: Up to Day 34

Measure: Multiple dose part - Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

Time: Up to Day 34

Measure: Multiple dose part - tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)

Time: Up to Day 34

Measure: Midazolam part - AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to Day 17

Measure: Midazolam part - Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to Day 17

2 Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)

The main objective of this trial is to investigate the influence of moderate and severe renal impairment on the pharmacokinetics of a single dose of BI 764198 in comparison to a group of matched controls with normal renal function.

NCT04176536

Conditions

Healthy
Chronic Kidney Disease

Interventions

Drug: BI 764198

MeSH:Kidney Diseases Renal Insufficiency, Chronic

HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to 96 hours

Measure: Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to 96 hours

Secondary Outcomes

Measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 the last quantifiable data point)

Time: Up to 96 hours

Related HPO nodes (Using clinical trials)

HP:0000077: Abnormality of the kidney

HP:0012622: Chronic kidney disease

Genes 127

PAX2 NPHP4 JAG1 SEC61A1 WT1 TMEM231 SDCCAG8 IQCB1 BICC1 COL4A4 TMEM67 WT1 TSC2 FAN1 NPHP1 IFT172 TBC1D8B SGPL1 MAGI2 GANAB NPHP4 NPHP3 CLCN5 CEP83 OCRL MUC1 NEK8 KYNU GLIS2 NUP160 TRPC6 TTC21B COL4A3 PYGM DCDC2 GATA3 TMEM67 SH2B1 CFH INF2 SAA1 AHI1 PKD2 CEP164 CFHR5 DNAJB11 CTNS INVS ALDOB CLCN5 IFT140 CD151 LAGE3 AGXT TMEM126B PKD1 NUP85 RAD51C TP53RK CEP290 MMUT SLC7A7 FN1 CEP290 ANLN DSTYK GSN XPNPEP3 MYO1E COQ8B IFT43 COL4A3 NUP205 CLDN16 IQCB1 WDR19 WDR19 NUP107 TSC1 FLT1 NUP93 DZIP1L NUP107 LAMB2 CORIN TMEM67 NOD2 SPRY2 INVS ARHGDIA NPHS2 TRAF3IP1 WDR19 TTC21B STOX1 LAMB2 PLCE1 DGKE MAPKBP1 CEP290 APOL1 NPHP4 CTNS CLDN19 UMOD PUS3 PAX2 NUP133 SARS2 TRAF3IP1 NPHP3 WDR19 PKD2 APRT LZTFL1 BNC2 HNF1B COL4A5 ACTN4 IFT122 NPHP1 CLCN5 TPRKB NPHP1 REN OSGEP SOX18

Protein Mutations 1

C677T

SNP 4

rs2281135 rs2294918 rs35652124 rs738409

HP:0000112: Nephropathy

Genes 118

PRODH DYNC2LI1 DYNC2H1 MYH9 FAM20A SEC61A1 TMEM231 TTR TMEM237 TREX1 WT1 PDX1 WIPF1 INPP5E WT1 LYZ CC2D2A KLF11 YWHAE WAS TRNF APOA1 TMEM138 ALG1 WAS SCNN1B TMEM237 WDR4 SAA1 DYNC2I1 GLA MAFB NEUROD1 UMOD NPHP1 COL4A1 MAFB ND1 ND4 OSGEP SLC26A4 NUP133 IFT140 CD151 BLK PAX6 COX1 CCND1 IFT140 IFT172 VIPAS39 WFS1 CEP290 KCNJ10 TRNW CC2D2A TRNQ RPGRIP1L ND5 WDR73 NLRP3 INS ND6 TP53RK FOXI1 APPL1 BSCL2 TMEM67 PAX4 NUP107 MEFV WDR19 KCNJ11 COX3 HIC1 HNF1A WT1 PRDX1 CAV1 RPGRIP1L NOD2 CEL MMACHC DYNC2I2 TPRKB SCARB2 HNF4A CLDN19 COX2 FGA VPS33B SCNN1A TRNS2 PAFAH1B1 FOS CISD2 WDR19 B2M EIF2AK3 HPRT1 GCK TMEM216 AGPAT2 LMX1B ABCC8 COL7A1 TRNS1 ADA2 IFT80 TRNL1 LAGE3 SCNN1G PPARG CAVIN1 TRNH ZNF423 CEP120 TTC21B

Protein Mutations 0

SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

Related HPO nodes (Using clinical trials)

HP:0000077: Abnormality of the kidney

Genes 1719

Protein Mutations 4

C282T C677T K55R Y93H

SNP 5

rs2281135 rs2294918 rs35652124 rs738409 rs7903146

HP:0012622: Chronic kidney disease

Genes 127

Protein Mutations 1

C677T

SNP 4

rs2281135 rs2294918 rs35652124 rs738409

HP:0000112: Nephropathy

Genes 118

Protein Mutations 0

SNP 0

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

Report Sections

See All Reports

BI 764198

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (2)

Correlated MeSH Terms (7)

Correlated HPO Terms (5)

Clinical Trials

NCT04102462

Conditions

Interventions

Primary Outcomes

Secondary Outcomes

2 Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design) Click for details

NCT04176536

Conditions

Interventions

MeSH:Kidney Diseases Renal Insufficiency, Chronic

HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Secondary Outcomes

Related HPO nodes (Using clinical trials)

Genes 1719

Protein Mutations 4

SNP 5

Genes 127

Protein Mutations 1

SNP 4

Genes 118

Protein Mutations 0

SNP 0

HPO

Related HPO nodes (Using clinical trials)

Genes 1719

Protein Mutations 4

SNP 5

Genes 127

Protein Mutations 1

SNP 4

Genes 118

Protein Mutations 0

SNP 0

Reports

2 Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)